In our latest, we tested elements of cancer biology research using @AnthropicAI AI agents, with varying amounts of human involvement across multi-step, multi-omic analyses
Interesting times for agentic AI & biological discovery, and for the future of (cancer) biology research...
We are hiring! We are specifically looking for a postgraduate associate - someone who has recently finished university and is ultimately looking to apply to medical school or graduate school.
It is a TWO YEAR clinical/translational position, where you will be interacting closely with patients, involved in translational clinical trials, and working hands on in the lab and with clinical databases.
The ideal candidate is a great communicator, organized, and enthusiastic about patient-oriented clinical and lab research. You will get dedicated mentoring not just on the science and clinic, but also on career/professional development as well.
We are looking for someone to start ASAP! More information here:
postdocs.yale.edu/posts/2026…
Please help to spread the word and RT!
@DrChoueiri@VanAllenLab@tompowles1@YaleCancer@YaleMed@SmilowCancer@kidneycan@OncoAlert@OncLive@KidneyCancer@A_P_S_A@cure_today@yalepathology@Yale_Urology@DrYukselUrun@MarkDSiegel1@OncBrothers@DrKarineTawagi
In our latest, a surprise - thanks to computational pathology - about immune cell clustering in prostate cancer and new ways to understand tumors, their neighborhoods, and clinical outcomes ... congrats @DYangMD et al! (link below)
A true joy celebrating the 25 year anniversary for @CampKesem last weekend with the one-and-only Iris Wedeking - a remarkable org, impacting cancer patients and their families ( inspiring clueless college kids like me!) ... a genuine privilege to be part of this family
Today at #AACR26: Noah Fields, MS, of @DanaFarber’s @VanAllenLab, presents findings from a familial cancer study suggesting that high-resolution germline genetic testing could benefit patients with familial cancer.
➡️ bit.ly/4crIeQl
LBA1/Plenary #ASCO26: PROTEUS trial
Perioperative apalutamide ADT vs. placebo ADT with radical prostatectomy in HR localized or locally advanced PC
Our very own #DrMaryEllenTaplin from @DanaFarber_GU will take the stage at #ASCO26 and present phase 3 PROTEUS trial. This is a key multimodal treatment question and could shift the paradigm on how we think about systemic therapy in the perioperative setting. Dr Taplin has worked on countless Neoadjuvant Strategies in prostate cancer and it is rewarding to see her work materialize at the big stage !
@DanaFarber@DanaFarber_GU@ASCO@OncoAlert
In our latest, we made examined simulation frameworks for biologically-informed neural networks in cancer genomics
and
showed how germline somatic integration shifts gene importance rankings (👋 BRCA2), even w/o gains in predictive accuracy...
Congrats Gwen Miller et al!
In our latest, we used single cell ATAC to take a deep dive into kidney cancer chromatin programs and their relation to mutations in epigenetic regulators interferon endogenous retroviruses - congrats Sabrina Camp, Kevin Bi et al!
Here, we found out how liposarcomas - rare cancers arising from adipose precursor cells - can switch from indolent to lethal states
A fascinating set of insights that even includes GLP-1 biology therapeutics in cancer!
Congrats Dr. Erica Pimenta et al @DanaFarber@ScienceTM